TLC177 is a liposomal encapsulated formulation of Doxorubicin, effectively reducing the side effects of doxorubicin and broadening indications.
- ✔ Disease& Specialty
- ✔ R&D Stage
- ✔ Collaboration Option
- ✔ Target Market
➤ New Drug
➤ Phase III
➤ Marketing & Distribution
➤ North America
Request for Collaboration
TLC's own formulation of liposome encapsulated doxorubicin effectively reduces the side effects of doxorubicin and broadens its indications.
Breast cancer / ovarian cancer / Kaposi's sarcoma
- Effectively reduce the side effects of drugs
- Broadens indications of doxorubicin